Pathogenesis and Glycemic Management of Type 2 Diabetes Mellitus: A Physiological Approach
- 1 April 2012
- journal article
- review article
- Vol. 15 (4) , 239-246
Abstract
Type 2 diabetes (T2DM) is an incompletely understood chronic, progressive multifactorial disease with insulin resistance and decreased beta-cell function playing dominant roles in its genesis. The worldwide incidence of the disease is rapidly increasing to pandemic proportions. The increase in incidence of T2DM is attributable to changes in lifestyle, diet and obesity, but other causes remain to be defined. The disease is a major cause of early mortality due to atherosclerosis and cardiovascular disease (CVD), and is the leading cause of blindness, leg amputations, and chronic renal disease. Hyperglycemia inT2DM becomes manifest once insulin secretion is no longer adequate for the metabolic demands of the individual. The approach to glycemic management of the disease is increasingly based on understanding the underlying pathophysiology. Efforts to maintain and preserve beta-cell function during the earlier phases of the disease may have important implications in prevention of subsequent complications of TDM. Finally, the approach to glycemic management of the disease should be individualized by considering the psycho-socio-economic condition of each patient, and glycemic targets should reflect presence of comorbid conditions, age of the patient, the stage of their disease in terms of duration, presence of macro- and micro-vascular complications, and propensity for severe hypoglycemia.Keywords
This publication has 47 references indexed in Scilit:
- UN High-Level Meeting on Non-Communicable Diseases: addressing four questionsThe Lancet, 2011
- Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetesMetabolism, 2011
- Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical ImplicationsThe American Journal of Medicine, 2011
- Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trialThe Lancet, 2010
- Twelve type 2 diabetes susceptibility loci identified through large-scale association analysisNature Genetics, 2010
- Overview of Newer Agents: Where Treatment Is GoingThe American Journal of Medicine, 2010
- Intensive glucose control and macrovascular outcomes in type 2 diabetesDiabetologia, 2009
- Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical UseThe American Journal of Medicine, 2009
- Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysisThe American Journal of Medicine, 2009
- Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetesNature Genetics, 2008